CA
COGT icon

Clearstead Advisors’s Cogent Biosciences COGT Stock Holding History

Clearstead Advisors’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.86K Buy
+48
New +$1.68K ﹤0.01% 2509
2026
Q1 		– Sell
-1
Closed -$36 – 2372
2025
Q4 		$36 Sell
1
-2
-67% -$56 ﹤0.01% 2641
2025
Q3 		$44 Buy
+3
New +$36 ﹤0.01% 2982

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Clearstead Advisors's COGT Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Cogent Biosciences (COGT) in Q2 2026: 48 shares worth $1.86K. The stake represents ﹤0.01% of the portfolio and ranks #2509 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in COGT as recently as Q4 2025.

Clearstead Advisors first reported a position in COGT in Q3 2025 and has held it in 3 quarters since. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Clearstead Advisors held 48 shares of Cogent Biosciences worth $1.86K as of Q2 2026.
  • Cogent Biosciences was a new Clearstead Advisors position in Q2 2026.
  • Cogent Biosciences made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2509 holding.
  • Clearstead Advisors first reported a position in Cogent Biosciences in Q3 2025 and has held it in 3 quarters since.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.